Swedish biopharmaceutical company Immunicum AB (STO:IMMU) has changed its corporate name to Mendus AB, effective immediately, the company announced on Thursday.
This change was approved by shareholders at the Annual General Meeting on 10 May 2022.
According to the company, this rebranding reflects its maturing clinical pipeline and its broader positioning in cancer recurrence immunotherapy.
Mendus will continue trading under the ticker symbol 'IMMU' on Nasdaq Stockholm. The company's new website is http://www.mendus.com.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886